I Mab Non Currrent Assets Other Over Time
| IMAB Stock | USD 0.95 0.01 1.06% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out I Mab Performance and I Mab Correlation. IMAB |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share 0.043 | Quarterly Revenue Growth (0.62) | Return On Assets (0.29) | Return On Equity (0.72) |
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Currrent Assets Other Analysis
Compare I Mab and related stocks such as BeiGene, Krystal Biotech, and Immunovant Non Currrent Assets Other Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BGNE | 312 K | 312 K | 312 K | 312 K | 502 K | 3.9 M | 4.7 M | 42.9 M | 13.2 M | 2.5 M | 24.6 M | 30.7 M | (186.5 M) | 35.7 M | 37.5 M |
| KRYS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 452 K | 1.5 M | 1.6 M | 74 K | 324 K | 263 K | 249.8 K |
| IMVT | 79.9 K | 79.9 K | 79.9 K | 79.9 K | 79.9 K | 79.9 K | 79.9 K | 79.9 K | 79.9 K | 246 K | 246 K | 246 K | 246 K | 282.9 K | 179.3 K |
| FHTX | 566 K | 566 K | 566 K | 566 K | 566 K | 566 K | 566 K | 566 K | 566 K | 11 K | 842 K | 2.4 M | 8 M | 2.8 M | 2.7 M |
| STTK | 23 K | 23 K | 23 K | 23 K | 23 K | 23 K | 23 K | 23 K | 23 K | 90 K | 349 K | 381 K | 3.1 M | 2.5 M | 2.7 M |
| GLUE | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 5.3 M | 278 K | 4.9 M | 3.2 M |
| KYMR | 199 K | 199 K | 199 K | 199 K | 199 K | 199 K | 199 K | 199 K | 199 K | 1.8 M | 11.5 M | (98.8 M) | (122 M) | 7.9 M | 8.3 M |
| NRIX | 321 K | 321 K | 321 K | 321 K | 321 K | 321 K | 321 K | 321 K | 317 K | 347 K | 3.1 M | 4.9 M | 4.7 M | 5.4 M | 5.7 M |
| LYEL | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 3.2 M | 3.9 M | 5 M | 4.5 M | 4.3 M |
| CGEM | 188 K | 188 K | 188 K | 188 K | 188 K | 188 K | 188 K | 188 K | 188 K | 188 K | 2.3 M | 147 K | 459 K | 527.9 K | 685.9 K |
| RVMD | 383 K | 383 K | 383 K | 383 K | 383 K | 383 K | 383 K | 383 K | 593 K | (8.3 M) | (19.1 M) | (14.5 M) | (23.4 M) | 10.1 M | 10.6 M |
| DSGN | 212 K | 212 K | 212 K | 212 K | 212 K | 212 K | 212 K | 212 K | 212 K | 212 K | 212 K | (85.5 K) | 459 K | 430 K | 279.3 K |
| ERAS | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 56 K | 451 K | 3.3 M | 4.8 M | 2.8 M | 2.5 M |
| ASND | 32 K | 32 K | 31 K | 33 K | 140 K | 270 K | 268 K | 293 K | 1.2 M | 1.5 M | 1.4 M | 1.8 M | 1.9 M | 2.1 M | 2.2 M |
| APLS | 37.2 K | 37.2 K | 37.2 K | 37.2 K | 37.2 K | 133.3 K | 64.5 K | 116.2 K | 1.1 M | 385.1 K | 18.9 M | 31.6 M | 15.8 M | 1.3 M | 1.2 M |
| AKRO | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 20 K | 29 K | 161 K | 417 K | 108 K | (1.0) | (0.95) |
| BPMC | 283 K | 283 K | 283 K | 283 K | 169 K | 1.8 M | 2.1 M | 5.9 M | 10.7 M | 15.4 M | 11.1 M | 19.8 M | 26.8 M | 40.9 M | 42.9 M |
I Mab and related stocks such as BeiGene, Krystal Biotech, and Immunovant Non Currrent Assets Other description
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.My Equities
My Current Equities and Potential Positions
| I Mab | IMAB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | China |
| Exchange | NASDAQ Exchange |
USD 0.95
Check out I Mab Performance and I Mab Correlation. For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
I Mab technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.